Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Non-cash Items (2021 - 2026)

Nuvectis Pharma has reported Non-cash Items over the past 6 years, most recently at $348281.0 for Q1 2026.

  • Quarterly results put Non-cash Items at $348281.0 for Q1 2026, down 80.69% from a year ago — trailing twelve months through Mar 2026 was $348281.0 (down 80.69% YoY), and the annual figure for FY2025 was $40708.0, down 85.77%.
  • Non-cash Items reached $348281.0 in Q1 2026 per NVCT's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $15.2 million in Q2 2023 and bottomed at $9750.0 in Q2 2022.
  • Median Non-cash Items over the past 5 years was $1.0 million (2025), compared with a mean of $1.8 million.
  • The largest annual shift saw Non-cash Items surged 155346.15% in 2023 before it tumbled 98.19% in 2024.
  • Over 5 years, Non-cash Items stood at $1.0 million in 2022, then rose by 26.39% to $1.3 million in 2023, then plummeted by 78.28% to $286000.0 in 2024, then skyrocketed by 260.49% to $1.0 million in 2025, then tumbled by 66.22% to $348281.0 in 2026.
  • Business Quant data shows Non-cash Items for NVCT at $348281.0 in Q1 2026, $1.0 million in Q4 2025, and $348281.0 in Q3 2025.